Cabaletta Bio, Inc.
CABAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 21, 2024 | Stifel Nicolaus | Ben Burnett | $32.00(+82%) | $17.54 | StreetInsider |
| Jan 3, 2023 | Wells Fargo | $14.00(+51%) | $9.30 | Benzinga | |
| Aug 30, 2022 | Morgan Stanley | Michael Ulz | $3.00(+139%) | $1.25 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 1, 2026 |
| Wells Fargo | maintain | Equal Weight | Aug 14, 2026 |
| Wells Fargo | maintain | Equal Weight | May 15, 2026 |
| Cantor Fitzgerald | maintain | Overweight | May 4, 2026 |
| Guggenheim | maintain | Buy | Mar 24, 2026 |
| Morgan Stanley | maintain | Overweight | Mar 24, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Oct 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 10, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Sep 5, 2025 |
| Citigroup | maintain | Buy | Aug 14, 2025 |
| Guggenheim | maintain | Buy | Aug 8, 2025 |
| Wells Fargo | maintain | Equal Weight | Aug 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 11, 2025 |
| Citigroup | maintain | Buy | May 16, 2025 |
| Guggenheim | maintain | Buy | May 16, 2025 |
| Guggenheim | maintain | Buy | May 15, 2025 |
| UBS | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| Wells Fargo | maintain | Equal Weight | Apr 1, 2025 |
| Guggenheim | maintain | Buy | Apr 1, 2025 |
| Morgan Stanley | maintain | Overweight | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 17, 2025 |
| Evercore ISI Group | downgrade | Outperform →In Line | Dec 20, 2024 |
| Wells Fargo | downgrade | Overweight →Equal Weight | Dec 19, 2024 |
Earnings History
Next report: Mar 18, 2027 · EPS est. $-0.32| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.28 | $-0.32 | — | $1.7M |
| Aug 13, 2026 | $-0.34 | $-0.37 | — | $1.7M |
| May 14, 2026 | $-0.39 | $-0.41 | — | $1.7M |
| Mar 23, 2026 | $-0.40 | $-0.45 | — | $833.3K |
| Nov 10, 2025 | $-0.44 | $-0.49 | — | — |
| Aug 7, 2025 | $-0.73 | $-0.71 | — | $4.2M |
| May 15, 2025 | $-0.71 | $-0.67 | — | — |
| Mar 31, 2025 | $-0.65 | $-0.65 | $1.6M | — |
News
100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data
PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule…
PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, i…
Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.
PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule…
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel